Chrysant George S, Nguyen P K
University of Oklahoma, Oklahoma City, USA.
Vasc Health Risk Manag. 2007;3(1):23-30.
Angiotensin-converting enzyme (ACE) inhibitors today are the standard therapy of patients with myocardial infarction and heart failure due to their proven beneficial effects in left ventricular remodeling and left ventricular function. ACE inhibitors have also been demonstrated to lead to regression of left ventricular hypertrophy (LVH). It is believed that the mechanism of action of LVH regression with ACE inhibitors arises from more than simple blood pressure reduction. LVH is an important risk factor for cardiovascular disease morbidity and mortality independent of blood pressure. Moexipril hydrochloride is a long-acting, non-sulfhydryl ACE inhibitor that can be taken once daily for the treatment of hypertension. Moexipril has now also been demonstrated to have beneficial effects on LVH and can lead to LVH regression.
如今，血管紧张素转换酶（ACE）抑制剂是心肌梗死和心力衰竭患者的标准治疗药物，因为它们在左心室重塑和左心室功能方面已被证实具有有益作用。ACE抑制剂也已被证明可导致左心室肥厚（LVH）消退。据信，ACE抑制剂使LVH消退的作用机制不仅仅源于单纯的血压降低。LVH是心血管疾病发病率和死亡率的一个重要危险因素，与血压无关。盐酸莫昔普利是一种长效、非巯基ACE抑制剂，可每日服用一次用于治疗高血压。现已证明，莫昔普利对LVH也有有益作用，并可导致LVH消退。
